Multiple strategies are employed to achieve this, including antibodies targeting CD47 or SIRPα binding sites [81,82], recombinant proteins competing with endogenous proteins for CD47 or SIRPα binding [83,84], and targeting the pathways regulating CD47 transcription to suppress its surface expression on cancer cells [85]. This evidence concerns the gene SIRPA and cancer.